Article thumbnail

REALITIES AND PROSPECTS FOR PHARMACOLOGICAL CORRECTION OF «ADMA-ENOS"-ASSOCIATED WAYS IN PREECLAMPSIA

By M. V. Pokrovsky, N. G. Filipenko, M. V. Korokin, V. V. Gureyev, T. G. Pokrovsky, A. A. Barsuk, L. V. Korokina, E. V. Proskuryakova, N. V. Maltseva, O. V. Levashova, O. S. Gudyrev, A. S. Belous and O. S. Polyanskaya

Abstract

Methylated analogs of L-arginine - asymmetric dimetilarginin (ADMA) and monometilarginin (L-NMMA) - are endogenous inhibitors of endothelial NO-synthase (eNOS). ADMA level in maternal plasma is increased in women with preeclampsia. The high level of ADMA is one of the predictors of preeclampsia. L-arginine increases the activity of eNOS and production of nitric oxide in the ADMA-similar model of L-NAME-induced endothelial dysfunction. ENOS activator (resveratrol), antioxidants, potentiated polyclonal antibodies to eNOS and others agents have been effective in this model. Studies of endotelioprotective activity in other «ADMA-eNOS-associated" experimental models of metabolic syndrome and homocysteine-induced, gipoestrogen-induced sepsis-induced endothelial dysfunction and endothelial dysfunction in postvaccinal vasculitis have been developed

Topics: endothelial dysfunction, preeclampsia, ADMA, eNOS, Therapeutics. Pharmacology, RM1-950, Diseases of the circulatory (Cardiovascular) system, RC666-701
Publisher: Stolichnaya Izdatelskaya Kompaniya
Year: 2010
DOI identifier: 10.20996/1819-6446-2010-6-6-882-887
OAI identifier: oai:doaj.org/article:2e2d0fe97be247eeb5bcd3a592b1aee3
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://doaj.org/toc/2225-3653 (external link)
  • https://doaj.org/toc/1819-6446 (external link)
  • https://doaj.org/article/2e2d0... (external link)
  • https://www.rpcardio.com/jour/... (external link)

  • To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

    Suggested articles